Wigs Medical Grade Market Global Industry Analysis and Forecast (2026–2035)

Wigs Medical Grade Market size was USD 1,100 Million in 2025, projected to reach USD 2,050 Million by 2035, growing at a CAGR of 6.4% from 2026 to 2035. Key drivers include rising cancer treatment volumes, Japan’s medical wig standard, and insurer-linked discounts, with North America leading the market.

Download Free Sample PDF
Base Year (2025)
$1,100.0 Million
Forecast (2035)
$2,050.0 Million
CAGR (2026-2035)
6.4%
Top Region
North America

What Is the Wigs Medical Grade Market Size?

The global Wigs Medical Grade Market reached USD 1,100 Million in 2025 and is estimated at USD 1,170 Million in 2026, forecast to reach USD 2,050 Million by 2035 at a CAGR of 6.4% between 2026 and 2035. North America leads with approximately 38% revenue share in 2025, while synthetic fiber is the dominant material at approximately 52%.

Medical-wig standards and access rules vary by country. Japan’s JIS S 9623:2015 is a national specification, while product recognition, reimbursement, and subsidy rules differ across other markets. We therefore size this market as wigs sold for medically related hair loss, a boundary that should be distinguished from broader fashion-wig estimates.

Wigs Medical Grade Market Global Industry Analysis and Forecast (2026–2035) Revenue Forecast

Values in USD Million

2025 $1,100.0 Million
2025
2026 $1,170.0 Million
2026
2027 $1,244.9 Million
2027
2028 $1,324.6 Million
2028
2029 $1,409.3 Million
2029
2030 $1,499.5 Million
2030
2031 $1,595.5 Million
2031
2032 $1,697.6 Million
2032
2033 $1,806.2 Million
2033
2034 $1,921.8 Million
2034
2035 $2,050.0 Million
2035

Key Takeaways

By Material: Synthetic fiber held the largest share, expanding from USD 572.00 Million in 2025 to USD 1,025.00 Million by 2035; blended hair is the fastest-growing at a 7.2% implied CAGR from 2025-2035.

By Cap Construction: Monofilament and hand-tied held the largest share, expanding from USD 440.00 Million in 2025 to USD 758.50 Million by 2035; silicone and medical adhesive base is the fastest-growing at 11.2% CAGR from 2026-2035.

By Customization: Ready-made held the largest share, expanding from USD 726.00 Million in 2025 to USD 1,271.00 Million by 2035; custom-made is the fastest-growing at 7.6% CAGR from 2026-2035.

By Medical Condition: Chemotherapy and radiation hair loss held the largest share, expanding from USD 572.00 Million in 2025 to USD 963.50 Million by 2035; other medical hair loss is the fastest-growing at 7.8% CAGR from 2026-2035.

By End User: Adult women held the largest share, expanding from USD 814.00 Million in 2025 to USD 1,435.00 Million by 2035; pediatric patients are the fastest-growing at 8.1% CAGR from 2026-2035.

By Sales Channel: Specialty salons and clinics held the largest share, expanding from USD 572.00 Million in 2025 to USD 963.50 Million by 2035; online sales are the fastest-growing at 7.9% CAGR from 2026-2035.

Dominant Region: North America dominated with approximately 38% revenue share in 2025, supported by high cancer diagnosis volumes and established fitting networks.

Fastest-Growing Region: Middle East & Africa is expected to register the highest implied CAGR of 8.8% during 2025-2035, from a small base.

Dominant Country: The U.S. led the market with an estimated USD 334.40 Million in 2025.

Fastest-Growing Country: India is the fastest-growing country covered, projected to expand from USD 22.00 Million in 2025 at an implied CAGR of 12.5% from 2025-2035.

Consumer Behaviour Analysis of the Wigs Medical Grade Industry

The infographic indicates that some patients plan wig purchases before hair loss begins, particularly when treatment-related alopecia is expected. Clinical guidance recommends arranging a wig while natural hair is still present when a patient chooses this option. Referral routes, fitting experience, scalp comfort, and the availability of financial support can influence supplier choice, while the final price depends partly on who pays.

What Does the Wigs Medical Grade Market Encompass?

The Wigs Medical Grade Market covers wigs made for people with medical hair loss, also called cranial prostheses. It includes ready-made and custom-made wigs in human, synthetic, and blended hair, sold through salons, hospitals, and online channels. It excludes fashion wigs, theatrical wigs, hair extensions, scalp-cooling devices, hair-transplant services, and headwear.

Japan issued JIS S 9623:2015, a national standard for medical wigs and accessories, on 20 April 2015. The standard was confirmed as current on 20 October 2025. The Japan Hair Association certifies products that meet the requirements and permits use of the M.Wig mark. Elsewhere, medical-wig recognition, funding, and reimbursement depend on local rules and payer policies. Market development therefore varies by country.

Market Drivers & Dynamics

Interactive Dataset
Rising cancer treatment volumes driver Positive Global 2026-2035
Medical wig standards and certification driver Positive Japan, with potential relevance elsewhere in Asia-Pacific 2026-2032
Insurer-linked discounts and public assistance schemes driver Positive Japan, Europe, North America 2026-2030
Specialist fitting and online access driver Positive North America, Europe 2026-2030
Hair-loss prevention therapies restraint Negative North America, Europe 2027-2035
Patient out-of-pocket cost restraint Negative England, North America, emerging regions 2026-2030
Unverified medical-grade claims restraint Negative Global 2026-2030
Short wear period for chemotherapy users restraint Negative Global 2026-2035
Source: Next Move Strategy Consulting

Growth Drivers

What Is the Primary Growth Driver of the Wigs Medical Grade Market?

Cancer treatment volumes provide the primary demand base. The American Cancer Society projects 2,114,850 new cancer cases in the United States in 2026. Some chemotherapy regimens and radiation treatments cause hair loss, although cancer incidence is a context indicator rather than a direct measure of wig purchases. NMSC estimates chemotherapy and radiation hair loss as the largest medical-condition segment at USD 572.00 Million in 2025.

How Are Payer Schemes Driving the Market Growth?

Funding rules influence who buys a wig and how much patients pay. In England, the NHS charges GBP 80.15 for a stock modacrylic wig, GBP 212.35 for a partial human hair wig, and GBP 310.55 for a full made-to-order human hair wig, subject to exemptions. NHS-supplied wigs are free in Scotland and Wales, while wigs are also provided free through health services in Northern Ireland. In Japan, selected employer-linked insurance products provide optional cancer-related support and discounts for eligible policyholders. These arrangements improve access but are not universal reimbursement.

Growth Inhibitors

What Is Restraining the Wigs Medical Grade Market?

Out-of-pocket cost and unclear product claims restrain growth. In England, patients who do not qualify for NHS exemptions pay the listed charges, while access and reimbursement vary by country and payer. Outside Japan, buyers may also face inconsistent use of the medical-grade label because no single global standard governs the market. NMSC assesses the effect as strongest where financial support and product-verification systems are limited.

What Are the Growth Opportunities?

How Can Pediatric and Alopecia Users Create Repeat Demand?

Children and people with long-term alopecia may need replacement wigs as they grow or as products wear out. NMSC projects pediatric patients to grow at an 8.1% CAGR from 2026 to 2035. Custom and size-adjustable suppliers may benefit. Realization depends on donor programs, age-appropriate styling, and local funding rules that allow replacement as children grow.

Where Do Silicone and Medical Adhesive Bases Add Value?

NMSC estimates that silicone and medical adhesive bases will rise from USD 86.58 Million in 2026 to USD 225.50 Million by 2035, equivalent to an 11.2% CAGR. Premium custom makers may benefit from demand for secure and skin-friendly bases. Success depends on appropriate skin-safety testing and clear fitting guidance, since poor adhesion can undermine patient confidence and increase returns.

How Can Hospital Programs Capture Early Buyers?

Hospital and cancer-center programs can reach patients around the time of diagnosis. NMSC estimates sales through this channel will reach USD 430.50 Million by 2035. Suppliers with in-hospital salons or fitting partnerships may benefit. Cancer centers can add wig-fitting referrals to existing supportive-care pathways, provided staff training and referral workflows are in place.

Segmentation Analysis

2025 (USD Million)
2035 (USD Million)
Synthetic fiber 2025: $572.0 Million | 2035: $1,025.0 Million
Synthetic fi
Human hair 2025: $385.0 Million | 2035: $738.0 Million
Human hair
Blended hair 2025: $143.0 Million | 2035: $287.0 Million
Blended hair
Synthetic fiber $572.0 Million $1,025.0 Million 6.0%
Human hair $385.0 Million $738.0 Million 6.7%
Blended hair $143.0 Million $287.0 Million 7.2%

Which Material Leads the Wigs Medical Grade Market and Which Grows Fastest?

Synthetic fiber leads with USD 572.00 Million in 2025, as lower prices suit short-term chemotherapy use and price-sensitive buyers. Blended hair is projected to grow fastest at a 7.2% implied CAGR from 2025 to 2035, as buyers seek a natural look at a moderate price. Human hair is projected to grow at a 6.7% implied CAGR from 2025 to 2035, supported by long-term alopecia users. These segment values and growth rates are NMSC estimates.

2025 (USD Million)
2035 (USD Million)
Category A
Category B
Category C
Category D
Segment Item 2025 (USD Million) 2035 (USD Million) CAGR
Category A $10.0 USD Million $40.0 USD Million 21.0%
Category B $17.1 USD Million $51.1 USD Million 11.0%
Category C $24.2 USD Million $62.2 USD Million 25.0%
Category D $31.3 USD Million $73.3 USD Million 11.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Cap Construction.

Unlock Full Data
2025 (USD Million)
2035 (USD Million)
Category A
Category B
Category C
Category D
Segment Item 2025 (USD Million) 2035 (USD Million) CAGR
Category A $10.0 USD Million $40.0 USD Million 23.0%
Category B $17.1 USD Million $51.1 USD Million 21.0%
Category C $24.2 USD Million $62.2 USD Million 27.0%
Category D $31.3 USD Million $73.3 USD Million 25.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Customization.

Unlock Full Data
2025 (USD Million)
2035 (USD Million)
Category A
Category B
Category C
Category D
Segment Item 2025 (USD Million) 2035 (USD Million) CAGR
Category A $10.0 USD Million $40.0 USD Million 16.0%
Category B $17.1 USD Million $51.1 USD Million 10.0%
Category C $24.2 USD Million $62.2 USD Million 20.0%
Category D $31.3 USD Million $73.3 USD Million 14.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Medical Condition.

Unlock Full Data
2025 (USD Million)
2035 (USD Million)
Category A
Category B
Category C
Category D
Segment Item 2025 (USD Million) 2035 (USD Million) CAGR
Category A $10.0 USD Million $40.0 USD Million 26.0%
Category B $17.1 USD Million $51.1 USD Million 16.0%
Category C $24.2 USD Million $62.2 USD Million 18.0%
Category D $31.3 USD Million $73.3 USD Million 8.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By End User.

Unlock Full Data
2025 (USD Million)
2035 (USD Million)
Category A
Category B
Category C
Category D
Segment Item 2025 (USD Million) 2035 (USD Million) CAGR
Category A $10.0 USD Million $40.0 USD Million 24.0%
Category B $17.1 USD Million $51.1 USD Million 10.0%
Category C $24.2 USD Million $62.2 USD Million 8.0%
Category D $31.3 USD Million $73.3 USD Million 14.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Sales Channel.

Unlock Full Data

Regulatory Framework Impacting the Wigs Medical Grade Industry

The infographic indicates that medical-wig status depends on national standards and local funding rules rather than one global regulatory framework. Japan defines general product specifications through JIS S 9623:2015 and the M.Wig certification mark. The United Kingdom shapes patient costs through NHS charges in England and free NHS supply in Scotland and Wales; Northern Ireland also provides wigs through its health services. Suppliers should document conformity to applicable standards and local product requirements to support payer discussions and buyer confidence.

Growth Opportunities

Our assessment indicates that three opportunities may broaden demand beyond treatment-related purchases.

How Can Pediatric and Alopecia Users Create Repeat Demand?

Children and people with long-term alopecia may need replacement wigs as they grow or as products wear out. NMSC projects pediatric patients to grow at an 8.1% CAGR from 2026 to 2035. Custom and size-adjustable suppliers may benefit. Realization depends on donor programs, age-appropriate styling, and local funding rules that allow replacement as children grow.

Where Do Silicone and Medical Adhesive Bases Add Value?

NMSC estimates that silicone and medical adhesive bases will rise from USD 86.58 Million in 2026 to USD 225.50 Million by 2035, equivalent to an 11.2% CAGR. Premium custom makers may benefit from demand for secure and skin-friendly bases. Success depends on appropriate skin-safety testing and clear fitting guidance, since poor adhesion can undermine patient confidence and increase returns.

How Can Hospital Programs Capture Early Buyers?

Hospital and cancer-center programs can reach patients around the time of diagnosis. NMSC estimates sales through this channel will reach USD 430.50 Million by 2035. Suppliers with in-hospital salons or fitting partnerships may benefit. Cancer centers can add wig-fitting referrals to existing supportive-care pathways, provided staff training and referral workflows are in place.

Regional Outlook

2025 (USD Million)
2035 (USD Million)
North Americ
Europe
Asia-Pacific
Middle East
Latin Americ
Region 2025 (USD Million) 2035 (USD Million) CAGR (%)
North America $10.0 USD Million $40.0 USD Million 9.0%
Europe $17.1 USD Million $51.1 USD Million 27.0%
Asia-Pacific $24.2 USD Million $62.2 USD Million 25.0%
Middle East & Africa $31.3 USD Million $73.3 USD Million 23.0%
Latin America $38.4 USD Million $84.4 USD Million 12.0%

Regional data is locked

Unlock complete regional numbers for this market.

Unlock Full Data

Competitive Landscape

Our analysis indicates that competition in the Wigs Medical Grade Market includes established manufacturers, specialist fitting businesses, and online retailers. The evidence reviewed does not establish verified global market shares.

Dimension Description
Market Structure Fragmented. Specialist salons, hospital programs, online sellers, and multinational groups serve patients. No independently verified global market-share dataset was identified.
Innovation Focus Soft and secure cap constructions, product conformity, hair-fiber quality, and custom fitting.
M&A Activity Limited in the sources reviewed. The verified 2025 developments include insurer partnerships and a hospital wig-donation program; no verified acquisition of a medical-wig maker was identified.

How Do Companies Compete in the Wigs Medical Grade Market?

Companies compete on fit, comfort, natural appearance, product conformity, and service. Salons compete through personal consultation, while online sellers compete on range and price. Aderans combines medical-wig brands with salon and in-hospital channels, and operates across 17 countries and regions. Pricing also reflects local funding rules and patient eligibility.

Which Company Archetypes Dominate?

Three archetypes shape the market. Integrated groups design, make, and sell wigs and may operate their own salons. Specialist cranial-prosthesis studios serve local patients with custom fitting. Online retailers sell ready-made products and offer a broader geographic reach. Public market-share disclosure is limited, so no single global leader can be established from the sources reviewed.

What Innovation and Differentiation Strategies Matter Most?

Differentiation rests on product conformity, patient comfort, and fit. Aderans states that its medical wigs fulfill JIS S 9623 requirements and that its Rafra brand has been offered since 2005. It reports ongoing work to improve softness, fit, and natural appearance. Smaller makers may differentiate through hand-tied hairlines and silicone bases, but public test evidence varies by supplier.

How Active Is M&A in the Wigs Medical Grade Market?

Deal activity appears limited in the sources reviewed. The reviewed evidence points to channel collaborations and patient-access initiatives rather than ownership transactions. No verified acquisition of a medical-wig maker in 2025 or 2026 was identified in the sources reviewed. The timing of wider salon or online-retailer consolidation therefore remains uncertain.

Key Market Players

Aderans Co., Ltd. ARTNATURE Inc. Reizvoll Co., Ltd. Freedom Wigs Ltd. Wigs Plus LLC Medical Wigs Femperial Ulofey Wigs

Latest Developments

The following 2025 announcements were verified and relate directly to medical wigs or access to them.

Date Event
November 2025 Aderans donated 100 wigs to the National Cancer Institute of Thailand and Buriram Hospital. The company also provided fitting, hair-cutting, and maintenance guidance at the hospitals.
February 2025 Aderans announced partnerships with Mitsui Sumitomo Insurance and Aioi Nissay Dowa Insurance to offer eligible policyholders optional support for cancer-related costs and discounts of 5% to 10% on medical wigs.

Investment Opportunities

Where Is Capital Concentrating in the Wigs Medical Grade Market?

Verified strategic activity is concentrated in commercial partnerships and hospital fitting channels rather than disclosed capital investment. NMSC’s interpretation points toward payer-linked channels and custom fitting as areas for supplier differentiation. Investors should treat unverified private-funding claims with caution because many specialist operators do not publish financial data.

How Does Infrastructure Investment Shape Capacity?

Capacity depends on skilled fitters, hair sourcing, hand-tying labor, and product testing. Aderans reports production facilities and alliance-partner facilities in Thailand, the Philippines, and Laos. Fitting capacity is located near hospitals and city salons. Suppliers that invest in training, quality control, and testing may build buyer confidence and differentiate from low-quality sellers.

How Do ESG Considerations Shape Wigs Medical Grade Investment?

ESG criteria center on patient welfare, sourcing, labor conditions, and product safety. Hair sourcing and labor conditions require traceable supply chains, while skin-safety testing supports patient confidence. Investors should favor suppliers that publish product-conformity and sourcing policies.

Key Benefits for Stakeholders

How Does This Report Help Wig Manufacturers and Salon Operators?

Manufacturers and salon operators receive segment sizing, channel growth rates, and regional outlooks for planning production and fitting capacity. The report indicates that custom wigs and silicone bases are projected to grow faster than ready-made wigs, and it identifies where public funding rules influence patient costs. Operators can benchmark product construction, standards, and channel mix against the forecast.

How Does This Report Help Hospitals, Payers and Patient Groups?

Hospitals, payers, and patient groups receive a view of demand by medical condition, user group, and funding route. The analysis shows how prices, standards, and subsidies differ across countries, and highlights access gaps for children and people with alopecia. Payers can use these findings to consider coverage that reflects patient need and product-quality requirements.

How Does This Report Help Investors and Financial Analysts?

Investors and financial analysts receive a forecast, growth rates by segment, and an assessment of market structure. The report separates published external facts from NMSC estimates, supporting more cautious valuation. It indicates recurring demand drivers, limited public disclosure, and payer partnerships as a visible commercial catalyst.

Key Market Segments Evaluated

By Material

  • Synthetic fiber
  • Human hair
  • Blended hair

By Cap Construction

  • Monofilament and hand-tied
  • Lace front and full lace
  • Silicone and medical adhesive base
  • Machine-made wefted

By Customization

  • Ready-made
  • Custom-made

By Medical Condition

  • Chemotherapy and radiation hair loss
  • Alopecia conditions
  • Other medical hair loss

By End User

  • Adult women
  • Adult men
  • Pediatric patients

By Sales Channel

  • Specialty salons and clinics
  • Hospital and cancer center programs
  • Online sales

By Region

  • North America 
    • U.S.
    • Canada
    • Mexico.
  • Europe 
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Finland
    • Netherlands
    • Rest of Europe.
  • Asia-Pacific 
    • China
    • India
    • Japan
    • South Korea
    • Taiwan
    • Indonesia
    • Vietnam
    • Australia
    • Philippines
    • Malaysia
    • Rest of APAC.
  • Middle East & Africa 
    • Saudi Arabia
    • UAE
    • Egypt
    • Israel
    • Turkey
    • Nigeria
    • South Africa
    • Rest of MEA.
  • Latin America 
    • Brazil
    • Argentina
    • Chile
    • Colombia
    • Rest of LATAM.

Conclusion & Recommendations

What Is the Long-Term Outlook for the Wigs Medical Grade Market?

The long-term outlook is steady. Revenue is forecast to rise from USD 1,170 Million in 2026 to USD 2,050 Million in 2035, reaching approximately 1.75 times the 2026 level at a 6.4% CAGR. Growth is supported by treatment volumes, alopecia demand, and payer-linked access, while prevention therapies and shorter wear periods may limit upside. North America remains the largest region, while the Middle East & Africa and Asia-Pacific gain share in the NMSC forecast.

What Strategic Positioning Recommendations Does NMSC Offer?

NMSC recommends that suppliers document conformity with applicable standards, build fitting capacity near hospitals, and develop payer partnerships. Premium makers should assess silicone and custom lines for patients with extensive hair loss. Value-focused suppliers should align products with public and insurer price limits. Suppliers should publish product-safety and sourcing evidence to distinguish verified quality from unsupported medical-grade claims.

How Strong Is the Investment Attractiveness of the Wigs Medical Grade Market?

Investment attractiveness is moderate. Demand is linked to cancer treatment and alopecia, yet the market is fragmented, and disclosure is limited. Operators with hospital relationships, documented product conformity, and payer agreements may be better positioned. Investors should review customer concentration, supplier-quality evidence, and exposure to hair-loss prevention therapies before committing capital.

What Are the Market Shifts and Key Risks in the Wigs Medical Grade Market?

Three shifts stand out: Japan has a national medical-wig standard, selected insurers have introduced medical-wig discounts, and online sales provide wider access. Key risks include prevention therapies that may reduce demand for chemotherapy-related wigs, price pressure from public funding limits, and unsupported product-quality claims. Limited company disclosure also makes competitive benchmarking difficult.

What Are the Primary Growth Pathways Through 2035?

Growth is expected to follow four pathways. Cancer treatment volumes provide a demand base. Alopecia and pediatric users may support repeat purchases. Silicone and custom constructions may increase value per unit. Hospital programs, insurer-linked discounts, and online sales can extend access to patients outside major cities.

Delivered Customizations

We have successfully delivered the following deep-dive customizations:

Client Request Customization Delivered Value Adds
Import-Export Trade Assessment
  • Country-wise import and export analysis of medical-grade wigs under HS 6704, split by human-hair and synthetic-hair categories.
  • Identifies key sourcing origins, export hubs, and trade-flow shifts to support supply chain and sourcing decisions.
Addressable Market Sizing
  • TAM, SAM, and VAM sizing of medical-grade wig demand, based on chemotherapy patients and alopecia prevalence by country.
  • Prioritizes countries and patient pools with the largest serviceable demand for market entry and expansion planning.
Historical Material Mix Analysis
  • Historical market value and volume analysis of medical-grade wigs by material type, covering human-hair and synthetic-hair segments.
  • Shows material-mix shifts over time, guiding product portfolio and material investment priorities.
Reimbursement & Payer Coverage Assessment
  • Country-level mapping of public insurance, private insurance, and HSA/FSA-type coverage rules for medical wigs and hair prostheses.
  • Reveals markets where reimbursement supports adoption, informing pricing strategy and payer-engagement priorities.
Chemotherapy-Linked Demand Mapping
  • Demand mapping by medical condition, linking chemotherapy patient volumes, treatment regimens, and alopecia areata prevalence to wig demand by cap construction and customization type.
  • Pinpoints high-need patient cohorts to target product design, cap construction, and oncology-focused outreach.
Customization & Cap Construction Price Benchmarking
  • Price-premium benchmarking across cap construction types (monofilament, lace, hand-tied, machine-made) and customization levels using published retail and trade unit-value data.
  • Quantifies premium segments and supports pricing and customization-tier optimization.

FAQs

Sources & References

1.

Aderans, partnership with Mitsui Sumitomo Insurance and Aioi Nissay Dowa Insurance (18 February 2025)

aderans.co.jp
2.

Aderans, donation of 100 wigs to two hospitals in Thailand (28 November 2025)

aderans.co.jp
3.

Aderans, appearance-care caps and scarf launch (1 July 2025; adjacent products excluded from market scope)

aderans.co.jp
4.

Aderans, current company profile (58 group companies in 17 countries and regions; February 2026)

aderans.co.jp
5.

Aderans, 2025 CSR Communication Report (production bases in Thailand, the Philippines, and Laos)

aderans.co.jp
6.

Aderans, JIS S 9623 product-conformity statement and Rafra brand information

aderans.co.jp
7.

Japan Standards Association, JIS S 9623:2015 specification record and 20 October 2025 confirmation

webdesk.jsa.or.jp
8.

NHS, wigs and fabric supports on the NHS (current England charges and exemptions)

nhs.uk
9.

NHS Business Services Authority, wigs and fabric supports (charges in England; free supply in Scotland and Wales)

nhsbsa.nhs.uk
10.

Macmillan Cancer Support, help with wigs and fabric-support costs (including Northern Ireland)

macmillan.org.uk
11.

Northern Ireland Direct, Help with health costs (wigs included in free prescriptions)

nidirect.gov.uk
12.

American Cancer Society, Cancer Statistics 2026

acsjournals.onlinelibrary.wiley.com
13.

World Health Organization, Global Status Report on Cancer 2026 news release (8 July 2026)

who.int
14.

National Cancer Institute, Hair Loss (Alopecia) and Cancer Treatment

cancer.gov
15.

ClinicalTrials.gov, DA-007 study for chemotherapy-induced alopecia (NCT06762548)

clinicaltrials.gov/study/NCT06762548
16.

UnitedHealthcare Oxford, Wigs administrative policy (effective 1 January 2025)

uhcprovider.com
17.

National Alopecia Areata Foundation, reimbursement guidance for cranial prostheses

naaf.org
18.

Verified Market Research, Medical Wigs Market (commercial competitor estimate; scope/methodology may differ)

verifiedmarketresearch.com
19.

Cognitive Market Research, Medical Wigs Market (commercial competitor estimate; scope/methodology may differ)

cognitivemarketresearch.com
20.

Dataintelo, Medical Wigs Market (commercial competitor estimate; scope/methodology may differ)

dataintelo.com

About the Author

Mayurima Roy

Mayurima Roy

Mayurima Roy is Research Analyst at Next Move Strategy Consulting, where she has spent 4 years working across the firm's full industry coverage rather than a single fixed vertical. Her work centers on structured research, ongoing trend tracking, competitive assessment, and insight-led content development, translating complex market data into clear, decision-ready narratives that support informed client decision-making across diverse global industries, market sectors, and world regions every day.

About the Reviewer

Supradip Baul

Supradip Baul

Supradip Baul is an accomplished business consultant and strategist with over a decade of rich experience in market intelligence, strategy, technology, and business transformation. His work has included rigorous qualitative and quantitative analysis across multiple industries, helping clients shape investment decisions and long-term roadmaps. Earlier in his career, he was associated with Gartner, where he contributed to industry-leading reports and market share analyses. He has worked with leading global companies and holds an MBA with a dual specialization in Marketing and Finance.

Download Free Sample

Henri Knyphausen

HENRI KNYPHAUSEN

Partner at Singulier [Ex-BCG]

Singulier

I recently engaged NEXTMSC.com for a commercial due diligence project within the intralogistics sector, and I am pleased to provide a reference based on my experience. In utilizing NEXTMSC.com's services, I found their report to offer valuable insights into market dynamics and key industry players. The initial report provided a solid foundation for our analysis. However, as we were investigating a smaller target in the market, and I had specific customization requests requiring additional research. These requests included detailed information on product portfolios of various players and sub-market sizes, both inclusive and exclusive of certain product categories. NEXTMSC.com demonstrated commendable responsiveness and agility in accommodating these customization requests. Within a timeframe of 1-2 weeks, they delivered a revised report that met our specific needs. Furthermore, they were receptive to my follow-up inquiries, ensuring clarity and understanding of the data provided. The final deliverable significantly contributed to our due diligence efforts. One of NEXTMSC.com's notable strengths lies in their qualitative research capabilities. However, for future engagements, I would recommend the inclusion of a quantified market model in Excel format. Such a model would offer the ability to conduct in-depth analyses and explore various market segments, including country-specific data and subcomponent breakdowns. Based on my positive experience, I would not hesitate to work with NEXTMSC.com again. Their responsiveness, willingness to accommodate customization requests, and commitment to delivering actionable insights make them a reliable partner for commercial research projects.

Mohit Agarwal

MOHIT AGARWAL

Chief Manager

DryChem India Pvt. Ltd.

Next Move Strategy Consulting is an amazing team of consultants. We required a market study report for our investors on top priority and the team went above and beyond our expectations to deliver the same with ample supporting data within a short time span enabling us to secure the investments and keep our project timeline maintained. Their professionalism, attention to detail, and timely delivery of actionable recommendations have left a lasting impression on our organization.

Ross J Mckenzie

ROSS J MCKENZIE

Business Insight Manager

Staysure Group

“Next MSC have been incredibly helpful in providing detailed & robust information on our market, alongside quantifying growth by different segments. The process to procure was simple and easy, with sample reports and regular contact to ensure we had what we needed. Succinct detail on their sources & methodologies is also greatly received, allowing transparency in this respect helps build trust in the detail you pay for. Joseph in particular was fantastic, and helped ensure efficient provision of the insight pack – thank you NMSC!”.

Amos Chang

AMOS CHANG

Strategy Consultant

Kardex Group

I have bought the intralogistics market reports from NMSC two times so far. Joseph and his team are always very helpful and flexible in responding to any customization requirements on the report. Their expertise in market reports really helps us steer the day-to-day business. I will definitely recommend and come back myself whenever there is a need.

Kevin Coker

KEVIN COKER

Founder, CEO and Board Diector

Proxima Clinical Research

I have been using Next MSC reports for product positioning in a new geography for a long time. They have by far the best reports I have found and the price is reasonable too!

Custom Market Research Services

We will customize the research for you if the listed report does not fully match your requirements.

Get 30% Free Customization

Select License

This website uses cookies to ensure you get the best experience on our website. Learn more

✖